Ainos Inc Stock Price, News & Analysis

Ainos (NASDAQ:AIMD) has announced a strategic partnership with Advanced Semiconductor Engineering (ASE) to implement AI-powered scent digitization in semiconductor manufacturing. The collaboration will integrate Ainos' patented AI Nose technology, which analyzes airborne chemicals into 'Smell IDs', into ASE's smart factories.

The AI Nose technology has demonstrated nearly 80% accuracy in identifying 22 different VOCs in Japanese semiconductor facilities. The system will enable real-time air quality monitoring, predictive maintenance, process optimization, and enhanced ESG compliance across ASE's 46 fully automated factories.

Under a legally binding MOU, the partnership aims to:

• Refine VOC detection for semiconductor environments
• Plan large-scale AI Nose deployment across ASE operations
• Explore broader industrial applications

Ainos (NASDAQ:AIMD) reported its fiscal year 2024 financial results, marking a transition from COVID-19 testing to advancing VELDONA® and AI Nose programs. The company's AI Nose program achieved up to 94% accuracy in clinical trials for women's health testing, while its VOC detection platform showed 80% accuracy in semiconductor applications.

Financial highlights include:

• Revenue declined to $20,729 in 2024 from $122,112 in 2023
• Net loss increased to $14.86M from $13.77M in 2023
• Cash position improved to $3.89M from $1.89M year-over-year
• R&D expenses rose to $8.41M from $7.32M
• SG&A expenses decreased to $5.40M from $5.64M

Key developments include a partnership with Taiwan Tanabe Seiyaku for VELDONA® manufacturing and IRB approval for Sjögren's syndrome clinical trials. The company plans to commence second-generation Ainos Flora clinical studies in H1 2025 and aims to submit IND applications to the FDA by H2 2025.

Ainos (NASDAQ:AIMD) has formed a strategic partnership with ugo Inc., a leading Japanese service robotics company, to integrate AI Nose technology into service robots. The collaboration, highlighted in a Water Tower Research report, marks a breakthrough in digitizing olfactory sensing.

The partnership aims to enhance robotic capabilities across industrial safety, public security, environmental monitoring, and healthcare. ugo, which leads Japan's service robot market share, deploys its robots in commercial buildings, data centers, factories, and public facilities.

The integration represents a significant advancement in robotics, adding smell capability to existing features like collision detection, AI-powered image recognition, and environmental sensing. Commercial deployment is expected by 2026, targeting the Japanese market, which accounts for 38% of worldwide robot production. The service robot market in Japan is projected to reach $1.2 billion by 2025, part of a $40.6 billion global market.

Ainos (NASDAQ:AIMD) and ugo, Japan's largest service robot company, announced a strategic partnership to develop the world's first smell-enabled robots by integrating Ainos' AI Nose technology with ugo's autonomous robotic platform.

The AI Nose technology, initially developed for medical diagnostics, has demonstrated nearly 80% accuracy in identifying 22 different volatile organic compounds (VOCs) in Japanese semiconductor facilities. The integration will enable robots to:

• Detect gas leaks and toxic chemicals in manufacturing plants
• Identify explosives and hazardous substances for public safety
• Monitor air quality and pollutants
• Analyze VOC samples for disease detection

The partnership will explore revenue opportunities through technology licensing, Robotics-as-a-Service (RaaS), cloud-based scent intelligence, and maintenance services. The development plan includes technology integration, pilot deployments, AI optimization, and global commercialization.

Ainos (NASDAQ:AIMD) has secured a significant Japanese patent (No. 7619659) for VELDONA®, its innovative oral interferon formulation designed to treat and prevent coronavirus infections. This follows a recent patent approval in Taiwan, strengthening the company's global IP portfolio in a market projected to exceed $16 billion by 2031.

The patent includes 15 key claims covering VELDONA's formulation, featuring low-dose administration under 1,000 IU, sublingual and buccal delivery mechanisms, and flexible dosage forms. Unlike traditional interferon therapies, VELDONA® doesn't require cold chain logistics, significantly reducing costs.

The technology offers dual benefits for coronavirus treatment and prevention, with proven broad-spectrum antiviral efficacy against multiple variants. VELDONA® addresses accessibility through non-invasive oral therapy, affordability by eliminating cold chain dependency, and enhanced safety through its low-dose formulation.

Ainos (NASDAQ:AIMD) received a Water Tower Research report highlighting its AI Nose technology developments and strategic milestones. The report focuses on four key areas: robotics integration, where Ainos seeks partnerships to enhance robot functionality with olfactory capabilities; smart manufacturing, achieving 80% accuracy in identifying 22 VOCs across 761 semiconductor factory samples, with mass production planned for 1H2025; elderly care monitoring in Japan, developing an AI-driven telehealth system for long-term care facilities; and women's health testing through Ainos Flora device, which showed 94% accuracy in detecting vaginal infections and STIs.

The report also covers VELDONA® clinical trials, scheduled to begin in 1H25 for Sjogren's syndrome and HIV-related oral warts in Taiwan, with completion expected in 2026. Animal health trials for FCGS are set to complete in 1H25, with U.S. IND applications planned for 2H25.

Ainos (NASDAQ:AIMD) has received a 180-day extension from Nasdaq to regain compliance with the minimum bid price requirement. The company was initially notified on July 15, 2024, that its stock price had been trading below the required $1.00 minimum for 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2). After the initial 180-day compliance period ending January 13, 2025, Nasdaq has granted Ainos an additional extension until July 14, 2025 to meet the minimum bid requirement.

The company's shares will continue to trade on the Nasdaq Capital Market during this extension period, with no immediate effect on its listing status.

Ainos (NASDAQ:AIMD) has announced its AI Nose technology for robotics applications and launched the Ainos Alliance initiative, inviting global robotics companies to collaborate. The AI Nose technology, developed over nearly a decade, combines AI and MEMS gas sensors to enable robots to detect smells, targeting applications in home safety, healthcare, and industrial environments.

The technology offers capabilities including gas leak detection, disease detection through VOC analysis, and environmental monitoring. This announcement comes amid significant market growth projections, with the global robotics market expected to reach $178.63 billion by 2030, and the electronic nose market projected to hit $65.79 billion by 2031.

Through the Ainos Alliance, robotics companies can access this patented technology to enhance their products' capabilities in industrial safety, healthcare, and smart living applications.

Ainos (NASDAQ:AIMD) has shared its achievements and future plans in a shareholder letter. The company is developing AI Nose technology through Smell ID, achieving 80% accuracy in VOC detection platform with plans for mass production in H1 2025. Their Ainos Flora device for women's health achieved up to 94% accuracy in clinical trials, with second-generation studies planned for H1 2025.

The company's VELDONA low-dose interferon therapy is advancing with clinical trials for Sjögren's Syndrome and HIV-related oral warts scheduled to begin in H1 2025. A strategic partnership with Taiwan Tanabe Seiyaku Co. will support VELDONA's manufacturing and commercialization. The company also plans to complete veterinary trials for feline chronic gingivostomatitis by H1 2025.